ข้ามไปยังเนื้อหา

Hengli

เนื้อหานี้ยังไม่มีในภาษาของคุณ

Hengli (衡力) is a China-market botulinum toxin type A brand associated with Lanzhou Biotechnique Development Co., Ltd. A July 6, 2023 Fosun Pharma filing identifies the brand and company among products already launched in mainland China. Sinopharm’s official directory names Lanzhou Biotechnique as its botulinum toxin type A production unit. (Fosun Pharma: regulatory announcement 🔗; Sinopharm: biological products 🔗)

The product’s development history is traced to the Lanzhou Institute of Biological Products. Prosigne and Lantox occur in the same product lineage, but regional names do not create a worldwide label or a common approval holder. (Lantox history and literature review — Toxins 🔗)

FieldReference point
China-market nameHengli (衡力)
Product descriptionBotulinum toxin type A for injection
Toxin typeA
ManufacturerLanzhou Biotechnique Development Co., Ltd. (Sinopharm biological products 🔗)
Historical development institutionLanzhou Institute of Biological Products
Literature terminologyLanbotulinumtoxinA is used in the 2021 review; it does not establish a universal regulatory name.

The 2021 review dates development to 1985, a Chinese Ministry of Health approval to 1993, and a subsequent license covering strabismus, blepharospasm, and hemifacial spasm to 1997. It reports an extension to moderate-to-severe glabellar lines in 2012. These are historical milestones, rather than a complete current Chinese indication list. (Lantox history and literature review — Toxins 🔗)

People’s Health reported an additional Hengli indication approved by China’s National Medical Products Administration on April 27, 2026: temporary improvement of benign masseter hypertrophy. The report does not supply the complete revised prescribing information or detailed patient criteria. (People’s Health: Hengli indication expansion 🔗)

Masseter hypertrophy concerns enlargement of a chewing muscle. An indication addressing enlargement does not establish approval for bruxism, temporomandibular disorders, or nonspecific jaw pain. The proposed U.S. Botox Cosmetic masseter indication has its own product and regulatory record.

A 2022 randomized Hengli study describes botulinum neurotoxin with associated proteins, and gelatin, dextran, and sucrose as formulation ingredients. The study concerned overactive bladder; its publication does not itself establish that use as an approved Chinese indication. (Hengli overactive-bladder trial — Frontiers in Pharmacology 🔗)

Ingredients alone do not establish greater or lesser safety, efficacy, duration, or immunogenicity than another brand. Shared type A biology also does not establish equivalent potency units: the Botox Cosmetic label excludes comparison or conversion of its units to other toxin preparations. (Botox Cosmetic prescribing information — DailyMed 🔗) The unit interpretation guide distinguishes vial unit counts from cross-product comparisons.

NameDocumented contextProduct-information boundary
HengliChina-market brand in the Fosun Pharma filingChinese indications require Chinese product-specific evidence.
ProsigneBrazilian product naming Lanzhou Biotechnique as producerCristália holds the Brazilian registration and import role.
LantoxName in the 2021 historical and clinical literature reviewLiterature usage does not establish present registration in a particular country.

The Prosigne patient label approved May 12, 2026 describes a lyophilized type A product in 50 U and 100 U vials containing gelatin, dextran 20, and sucrose. It names Lanzhou Biotechnique Development as producer and Cristália Produtos Químicos Farmacêuticos Ltda. as registration holder and importer. These Brazilian facts do not establish Hengli’s current Chinese presentations or label. (Prosigne patient information — Cristália 🔗)

1. Which company role is supported by the Sinopharm directory?
2. What can the Brazilian Prosigne label establish about Hengli?
3. A randomized Hengli study concerns overactive bladder. What further evidence establishes approval for that use?